Table 4. Mean differences between eplerenone and control group after 24 weeks adjusted for baseline values.

	Δ Eplerenone – Δ Control, (adjusted)	P-values
	Mean (95% CI)
Indices of arterial stiffness
cfPWV (m/s)	0.1 (−1.0,1.3)	0.8
AIx (%)	4.4 (0.1, 8.6)	0.04
AIx@HR75 (%)	3.8 (0.3, 7.4)	0.04
AASI (units)	0.01 (−0.08, 0.09)	0.9
Blood pressure data
systolic office BP (mmHg)	4 (−3, 11)	0.2
diastolic office BP (mmHg)	3 (−1, 7)	0.1
central systolic BP (mmHg)	5 (−2, 13)	0.2
central diastolic BP (mmHg)	3 (−1, 7)	0.1
24 h systolic BP (mmHg)	3 (−2, 8)	0.2
24 h diastolic BP (mmHg)	2 (−2, 5)	0.4
Renal data
P-creatinine (mg/dL)	−0.19 (0.38, 0.00)	0.05
P-urea (mg/dL)	−8.4 (−16.8, −2.8)	0.1
P-potassium (mEq/L)	−0.2 (−0.5, 0.0)	0.1
P-bicarbonate (mEq/L)	0 (−2, 2)	0.9
eGFR (mL/min/1.73 m2)	3 (−1, 6)	0.2
Creatinine clearance (mL/min)	4 (−3, 11)	0.3
Urinary albumin (%)*	0.61 (0.37, 1.01)**	0.05

Note: Conversion factors for units: p-creatinine in mg/dL to µmol/L, ×88.4; p-urea in mg/dL to mmol/L, ×0.357. No conversion necessary for p-potassium or p-bicarbonate in mEq/L and mmol/L.

AASI, Ambulatory Arterial Stiffness Index; AIx, Augmentation Index; AIx@HR75, Augmentation Index adjusted for heart rate 75 beats/minute; BP, blood pressure; cfPWV, carotid-femoral pulse wave velocity; CI, confidence interval; eGFR, estimated glomerular filtration rate;

Indices of arterial stiffness are a mean of two measurements per patient, except AASI.

^*24 h urinary albumin excretion is presented as geometric means with 95% CI and ratio in percent.

^**Effect size, Δ Eplerenone – Δ Control, is given as ratio between eplerenone group and control group.

Multiple linear regression analysis was applied to compare the changes in the two groups with adjustment for the baseline values of the particular variable.